A carregar...
Andexanet Alfa: First Global Approval
Intravenous andexanet alfa [coagulation factor Xa (recombinant), inactivated-zhzo; Andexxa(®)] is a first-in-class recombinant modified factor Xa protein that has been developed by Portola Pharmaceuticals as a universal antidote to reverse anticoagulant effects of direct or indirect factor Xa inhibi...
Na minha lista:
| Publicado no: | Drugs |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer International Publishing
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6061403/ https://ncbi.nlm.nih.gov/pubmed/29926311 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-018-0940-4 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|